Published Year: 2019
Global NGS Sample Preparation Market: Focus on Product (Workstation (Open System, Closed System), St
The NGS sample preparation industry analysis by BIS Research projects the market to grow at a...
1.1 Inclusion and Exclusion
A quick peek into the report
Report Description
Market Report Coverage - Precision Medicine Forecast Period: 2020-2030 CAGR During Forecast Period: 11.13%
Key Questions Answered in this Report:
What are the estimated and projected numbers for the global precision medicine market for 2020 and 2030?
Market Overview
The global precision medicine market is projected to reach $278.61 billion by 2030.
Table of Contents
1 Product Definition
2 Research Scope
2.1 Scope of Study
2.2 Key Questions Answered in the Report
2.3 Global Precision Medicine Market: Research Methodology
2.4 Criteria for Company Profiling
3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
4 Global Precision Medicine Market Overview
4.1 Market Definition
4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
4.4 Initiatives and Programs
4.5 Precision Medicine: Enabling Technologies and Applications
4.5.1 Innovators
4.5.1.1 3D DNA Printing
4.5.1.1.1 Introduction
4.5.1.1.2 Role of 3D DNA Printing
4.5.1.2 RNA-Seq
4.5.1.2.1 Introduction
4.5.1.2.2 Role of RNA-Seq in Precision Medicine
4.5.1.2.3 Key Players
4.5.1.3 4D Molecular Imaging
4.5.1.3.1 Introduction
4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
4.5.1.3.3 Key Players
4.5.2 Early Adopters
4.5.2.1 CRISPR
4.5.2.1.1 Introduction
4.5.2.1.2 Role of CRISPR in Precision Medicine
4.5.2.1.3 Key Players
4.5.2.2 Blockchain
4.5.2.2.1 Introduction
4.5.2.2.2 Role of Blockchain in Precision Medicine
4.5.2.2.3 Key Players
4.5.2.3 Imaging Informatics
4.5.2.3.1 Introduction
4.5.2.3.2 Role of Imaging Informatics in Precision Medicine
4.5.2.3.3 Key Players
4.5.3 Early Majority
4.5.3.1 Artificial Intelligence (AI)
4.5.3.1.1 Introduction
4.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
4.5.3.1.3 Key Players
4.5.3.2 Circulating Free DNA (cfDNA)
4.5.3.2.1 Introduction
4.5.3.2.2 Role of cfDNA in Precision Medicine
4.5.3.2.3 Key Players
4.5.3.3 Big Data
4.5.3.3.1 Introduction
4.5.3.3.2 Role of Big Data in Precision Medicine
4.5.3.3.3 Key Players
4.5.3.4 Next-Generation Sequencing (NGS)
4.5.3.4.1 Introduction
4.5.3.4.2 Role of NGS in Precision Medicine
4.5.3.4.3 Key Players
4.5.3.5 Health Informatics
4.5.3.5.1 Introduction
4.5.3.5.2 Role of Health Informatics in Precision Medicine
4.5.3.5.3 Key players
4.5.3.6 Bioinformatics
4.5.3.6.1 Introduction
4.5.3.6.2 Role of Bioinformatics in Precision Medicine
4.5.3.6.3 Key Players
4.5.4 Late Majority
4.5.4.1 Polymerase Chain Reactions (PCR)
4.5.4.1.1 Introduction
4.5.4.1.2 Role of PCR in Precision Medicine
4.5.4.1.3 Key players
4.5.4.2 Microarray
4.5.4.2.1 Role of Microarray in Precision Medicine
4.5.4.2.2 Key Players
4.6 COVID-19 Impact on the Global Precision Medicine Market
5 Market Dynamics
5.1 Overview
5.2 Market Drivers
5.2.1 Advancement of Sequencing Technologies
5.2.2 Rising Prevalence of Chronic Diseases
5.2.3 Growing Demand for Preventive Care
5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
5.3 Market Restraints
5.3.1 Unified Framework for Data Integration
5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction
5.3.3 Lack of Robust Reimbursement Landscape
5.3.4 Regulatory Hurdles
5.4 Market Opportunities
5.4.1 Targeted Gene Therapy
5.4.2 Expansion into the Emerging Markets
5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry
6 Industry Insights
6.1 Patent Analysis
6.2 Legal Requirements and Regulations
6.3 Pipeline Analysis
6.4 Legal Requirements and Framework by the FDA
6.5 Legal Requirements and Framework by the EMA
6.6 Legal Requirements and Framework by the MHLW
7 Competitive Landscape
7.1 Synergistic Activities
7.1.1 Product launches, Enhancements, and Upgradation
7.1.2 Product Approvals
7.1.3 Mergers and Acquisitions
7.1.4 Business Expansion
7.2 Market Share Analysis
7.2.1 Market Share Analysis by Applied Sciences, 2019
7.2.2 Market Share Analysis by Precision Diagnostics, 2019
7.2.3 Market Share Analysis by Precision Therapeutics, 2019
7.2.4 Market Share Analysis by Digital Health and IT, 2019
8 Global Precision Medicine Market (by Ecosystem)
8.1 Overview
8.2 Applied Sciences
8.2.1 Genomics
8.2.2 Global Precision Medicine Genomics Market (by Technology)
8.2.2.1 Polymerase Chain Reaction (PCR)
8.2.2.1.1 Global Precision Medicine PCR Market (by Product)
8.2.2.1.2 Global Precision Medicine PCR Market (by End User)
8.2.2.1.3 Global Precision Medicine PCR Market (by Region)
8.2.2.2 Next-Generation Sequencing (NGS)
8.2.2.2.1 Global Precision Medicine NGS Market (by Product)
8.2.2.2.2 Global Precision Medicine NGS Market (by Technology)
8.2.2.2.3 Global Precision Medicine NGS Market (by End User)
8.2.2.2.4 Global Precision Medicine NGS Market (by Region)
8.2.2.3 Genome Editing
8.2.2.3.1 Global Precision Medicine Genome Editing Market (by Product)
8.2.2.3.2 Global Precision Medicine Genome Editing Market (by End User)
8.2.2.3.3 Global Precision Medicine Genome Editing Market (by Region)
8.2.2.4 Other Technologies
8.2.2.4.1 Global Precision Medicine Other Technologies Market (by Region)
8.2.3 Pharmacogenomics
8.2.3.1 Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services)
8.2.3.2 Global Precision Medicine Pharmacogenomics Market (by End User)
8.2.3.3 Global Precision Medicine Pharmacogenomics Market (by Region)
8.2.4 Other Applied Sciences
8.3 Precision Diagnostics
8.3.1 Molecular Diagnostics (MDx)
8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)
8.3.2.1 Non-Invasive Prenatal Testing (NIPT)
8.3.2.1.1 Global Precision Medicine NIPT Market (by Platform)
8.3.2.1.2 Global Precision Medicine NIPT Market (by Region)
8.3.2.2 Companion Diagnostics
8.3.2.2.1 Global Precision Medicine Companion Diagnostics Market (by Technology)
8.3.2.2.2 Global Precision Medicine Companion Diagnostics Market (by Indication)
8.3.2.2.3 Global Precision Medicine Companion Diagnostics Market (by Region)
8.3.2.3 Liquid Biopsy
8.3.2.3.1 Global Precision Medicine Liquid Biopsy Market (by Indication)
8.3.2.3.2 Global Precision Medicine Liquid Biopsy Market (by Region)
8.3.2.4 Other Molecular Diagnostics
8.3.2.4.1 Global Precision Medicine Other Molecular Diagnostics Market (by Type)
8.3.2.4.2 Global Precision Medicine Other Molecular Diagnostics Market (by Region)
8.3.3 Medical Imaging
8.3.3.1 Global Precision Medicine Medical Imaging Market (by Type)
8.3.3.1.1 Imaging Analytics
8.3.3.1.2 Imaging Computer-Aided Detection (CADx)
8.3.3.2 Global Precision Medicine Medical Imaging Market (by Region)
8.4 Digital Health and Information Technology
8.4.1 Global Precision Medicine Digital Health and Information Technology Market (by Type)
8.4.1.1 Clinical Decision Support Systems (CDSS)
8.4.1.2 Big Data Analytics
8.4.1.3 IT Infrastructure
8.4.1.3.1 Global Precision Medicine IT Infrastructure Market (by Type)
8.4.1.4 Genomics Informatics
8.4.1.4.1 Global Precision Medicine Genomics Informatics Market (by Product Type)
8.4.1.5 In-Silico Informatics
8.4.1.6 Mobile Health
8.4.2 Global Precision Medicine Digital Health and Information Technology Market (by End User)
8.4.3 Global Precision Medicine Digital Health and Information Technology Market, (by Region)
8.5 Precision Therapeutics
8.5.1 Global Precision Medicine Therapeutics Market (by Type)
8.5.1.1 Clinical Trials
8.5.1.1.1 Global Precision Medicine Clinical Trials Market (by Region)
8.5.1.2 Cell Therapy
8.5.1.2.1 Global Precision Medicine Cell Therapy Market (by Region)
8.5.1.3 Drug Discovery and Research
8.5.1.3.1 Global Precision Medicine Drug Discovery and Research Market (by Region),
8.5.1.4 Gene Therapy
8.5.1.4.1 Global Precision Medicine Drug Discovery and Research Market (by Region)
9 Global Precision Medicine Market (by Application)
9.1 Overview
9.2 Oncology
9.2.1 Cancer Precision Medicine Drugs and Indications
9.3 Infectious Diseases
9.3.1 Infectious Diseases Precision Medicine Drugs and Indications
9.4 Neurology
9.4.1 Neurology Precision Medicine Drugs and Indications
9.5 Cardiovascular
9.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
9.6 Lifestyle and Endocrinology
9.6.1 Endocrinology Precision Medicine Drugs and Indications
9.7 Gastroenterology
9.7.1 Gastroenterology Precision Medicine Drugs and Indications
9.8 Other Applications
9.8.1 Precision Drugs for Other Applications
10 Global Precision Medicine Market, (by Region)
10.1 Overview
10.2 North America
10.2.1 North America Precision Medicine Market (by Ecosystem)
10.2.2 U.S.
10.2.2.1 Overview of Precision Medicine
10.2.2.2 Key Trends
10.2.2.3 Promoting Factors
10.2.2.4 Recent Key Developments
10.2.2.5 Funding Scenario/Investments
10.2.2.6 Regulatory Scenario
10.2.2.7 Key Players
10.2.3 Canada
10.2.3.1 Overview of Precision Medicine
10.2.3.2 Key Trends
10.2.3.3 Promoting Factors
10.2.3.4 Recent Key Developments
10.2.3.5 Regulatory Scenario
10.2.3.6 Key Players
10.3 Europe
10.3.1 Europe Precision Medicine Market (by Ecosystem)
10.3.2 Germany
10.3.2.1 Overview of Precision Medicine
10.3.2.2 Key Trends
10.3.2.3 Promoting Factors
10.3.2.4 Recent Key Developments
10.3.2.5 Key Players
10.3.3 France
10.3.3.1 Overview of Precision Medicine
10.3.3.2 Key Trends
10.3.3.3 Promoting Factors
10.3.3.4 Recent Key Developments
10.3.3.5 Key Players
10.3.4 Italy
10.3.4.1 Overview of Precision Medicine
10.3.4.2 Key Trends
10.3.4.3 Promoting Factors
10.3.4.4 Recent Key Developments
10.3.4.5 Funding Scenario/Investments
10.3.5 U.K.
10.3.5.1 Overview of Precision Medicine
10.3.5.2 Key Trends
10.3.5.3 Promoting Factors
10.3.5.4 Recent Key Developments
10.3.5.5 Funding Scenario/Investments
10.3.5.6 Key Players
10.3.6 Spain
10.3.6.1 Overview of Precision Medicine
10.3.6.2 Key Trends
10.3.6.3 Promoting Factors
10.3.6.4 Recent Key Developments
10.3.6.5 Key Players
10.3.7 Rest-of-Europe
10.3.7.1 Switzerland
10.4 Asia-Pacific
10.4.1 Asia-Pacific Precision Medicine Market (by Ecosystem)
10.4.2 China
10.4.2.1 Overview of Precision Medicine
10.4.2.2 Key Trends
10.4.2.3 Promoting Factors
10.4.2.4 Recent Key Developments
10.4.2.5 Key Players
10.4.3 Japan
10.4.3.1 Overview of Precision Medicine
10.4.3.2 Key Trends
10.4.3.3 Promoting Factors
10.4.3.4 Recent Key Developments
10.4.3.5 Reimbursement Scenario
10.4.3.6 Key Players
10.4.4 Australia
10.4.4.1 Overview of Precision Medicine
10.4.4.2 Key Trends
10.4.4.3 Promoting Factors
10.4.4.4 Recent Key Developments
10.4.4.5 Regulatory Scenario
10.4.4.6 Key Players
10.4.5 India
10.4.5.1 Overview of Precision Medicine
10.4.5.2 Key Trends
10.4.5.3 Promoting Factors
10.4.5.4 Recent Key Developments
10.4.5.5 Key Players
10.4.6 Rest-of-Asia-Pacific (RoAPAC)
10.4.6.1 Singapore
10.4.6.1.1 Regulatory Framework
10.4.6.2 South Korea
10.4.6.3 Vietnam
10.5 Latin America
10.5.1 Latin America Precision Medicine Market (by Ecosystem)
10.5.2 Brazil
10.5.2.1 Overview of Precision Medicine
10.5.3 Mexico
10.5.3.1 Overview of Precision Medicine
10.5.3.2 Recent Key Developments
10.5.4 Rest-of-Latin America (RoLA)
10.6 Rest-of-the-World (RoW)
10.6.1 Rest-of-the-World Precision Medicine Market (by Ecosystem)
10.6.1.1 Israel
10.6.1.2 Saudi Arabia
10.6.1.3 United Arab Emirates
10.6.1.4 South Africa
10.6.1.5 Russia
11 Company Profiles
11.1 Overview
11.2 Abbott Laboratories
11.2.1 Company Overview
11.2.2 Role of Abbott Laboratories in Global Precision Medicine Market
11.2.3 Financials
11.2.4 Key Insights About Financial Health of the Company
11.2.5 SWOT Analysis
11.3 Almac Group Ltd.
11.3.1 Company Overview
11.3.2 Role of Almac Group Ltd. in Global Precision Medicine Market
11.3.3 SWOT Analysis
11.4 Amgen Inc.
11.4.1 Company Overview
11.4.2 Role of Amgen Inc. in Global Precision Medicine Market
11.4.3 Financials
11.4.4 Key Insights about Financial Health of the Company
11.4.5 SWOT Analysis
11.5 ANGLE plc
11.5.1 Company Overview
11.5.2 Role of ANGLE plc in Global Precision Medicine Market
11.5.3 Financials
11.5.4 Key Insights about Financial Health of the Company
11.5.5 SWOT Analysis
11.6 Astellas Pharma Inc.
11.6.1 Company Overview
11.6.2 Role of Astellas Pharma Inc.in Global Precision Medicine Market
11.6.3 Financials
11.6.4 Key Insights about Financial Health of the Company
11.6.5 SWOT Analysis
11.7 Astra Zeneca
11.7.1 Company Overview
11.7.2 Role of Astra Zeneca in Global Precision Medicine Market
11.7.3 Financials
11.7.4 SWOT Analysis
11.8 ASURAGEN INC.
11.8.1 Company Overview
11.8.2 Role of ASURAGEN Inc. in Global Precision Medicine Market
11.8.3 SWOT Analysis
11.9 Bio-Rad Laboratories, Inc.
11.9.1 Company Overview
11.9.2 Role of Bio-Rad Laboratories, Inc. in Global Precision Medicine Market
11.9.3 Financials
11.9.4 SWOT Analysis
11.10 bioMérieux S.A.
11.10.1 Company Overview
11.10.2 Role of bioMérieux SA. in Global Precision Medicine Market
11.10.3 Financials
11.10.4 SWOT Analysis
11.11 Bristol-Myers Squibb Company
11.11.1 Company Overview
11.11.2 Role of Bristol-Myers Squibb Company in Global Precision Medicine Market
11.11.3 Financials
11.11.4 Key Insights about Financial Health of the Company
11.11.5 SWOT Analysis
11.12 Cardiff Oncology
11.12.1 Company Overview
11.12.2 Role of Cardiff Oncology in Global Precision Medicine Market
11.12.3 Financials
11.12.4 Key Insights About Financial Health of the Company
11.12.5 SWOT Analysis
11.13 CETICS Healthcare Technologies GmbH
11.13.1 Company Overview
11.13.2 Role CETICS Healthcare Technologies GmbH in Global Precision Medicine Market
11.13.3 SWOT Analysis
11.14 Danaher Corporation
11.14.1 Company Overview
11.14.2 Role of Danaher Corporation in Global Precision Medicine Market
11.14.3 Financials
11.14.4 SWOT Analysis
11.15 Eli Lilly and Company Limited
11.15.1 Company Overview
11.15.2 Role of Eli Lilly and Company Limited in Global Precision Medicine Market
11.15.3 Financials
11.15.4 SWOT Analysis
11.16 Epic Sciences, Inc.
11.16.1 Company Overview
11.16.2 Role Epic Sciences, Inc. in Global Precision Medicine Market
11.16.3 SWOT Analysis
11.17 F. Hoffmann-La Roche Ltd
11.17.1 Company Overview
11.17.2 Role of F. Hoffman-LA Roche Ltd in Global Precision Medicine Market
11.17.3 Financials
11.17.4 Key Insights About Financial Health of the Company
11.17.5 SWOT Analysis
11.18 General Electric Company
11.18.1 Company Overview
11.18.2 Role of GE Corporation in Global Precision Medicine Market
11.18.3 Financials
11.18.4 Key Insights about Financial Health of the Company
11.18.5 SWOT Analysis
11.19 Gilead Sciences, Inc.
11.19.1 Company Overview
11.19.2 Role of Gilead Sciences, Inc. in Global Precision Medicine Market
11.19.3 SWOT Analysis
11.20 GlaxoSmithKline plc
11.20.1 Company Overview
11.20.2 Role of GlaxoSmithKline Plc in Global Precision Medicine Market
11.20.3 Financials
11.20.4 Key Insights about Financial Health of the Company
11.20.5 SWOT Analysis
11.21 Illumina, Inc.
11.21.1 Company Overview
11.21.2 Role of Illumina, Inc. in Global Precision Medicine Market
11.21.3 Financials
11.21.4 Key Insights About Financial Health of the Company
11.21.5 SWOT Analysis
11.22 Intomics A/S
11.22.1 Company Overview
11.22.2 Role Intomics A/S in Global Precision Medicine Market
11.22.3 SWOT Analysis
11.23 Johnson & Johnson Services, Inc.
11.23.1 Company Overview
11.23.2 Role of Johnson and Johnson in Global Precision Medicine Market
11.23.3 Financials
11.23.4 Key Insights about Financial Health of the Company
11.23.5 SWOT Analysis
11.24 Konica Minolta, Inc.
11.24.1 Company Overview
11.24.2 Role of Konica Minolta, Inc. in Global Precision Medicine Market
11.24.3 Financials
11.24.4 SWOT Analysis
11.25 Laboratory Corporation of America Holdings
11.25.1 Company Overview
11.25.2 Role of Laboratory Corporation of America Holdings in Global Precision Medicine Market
11.25.3 Financials
11.25.4 SWOT Analysis
11.26 MDx Health, Inc.
11.26.1 Company Overview
11.26.2 Role of MDx Health, Inc. in Global Precision Medicine Market
11.26.3 Financials
11.26.4 SWOT Analysis
11.27 Menarini Silicon Biosystems, Inc.
11.27.1 Company Overview
11.27.2 Role Menarini Silicon Biosystems, Inc. in Global Precision Medicine Market
11.27.3 SWOT Analysis
11.28 Merck KGaA
11.28.1 Company Overview
11.28.2 Role of Merck KGaA in Global Precision Medicine Market
11.28.3 Financials
11.28.4 Key Insights About Financial Health of the Company
11.28.5 SWOT Analysis
11.29 Myriad Genetics, Inc.
11.29.1 Company Overview
11.29.2 Role of Myriad Genetics, Inc. in Global Precision Medicine Market
11.29.3 Financials
11.29.4 Key Insights About Financial Health of the Company
11.29.5 SWOT Analysis
11.30 Novartis AG
11.30.1 Company overview
11.30.2 Role of Novartis AG in Global Precision Medicine Market
11.30.3 Financials
11.30.4 Key Insights about Financial Health of the Company
11.30.5 SWOT Analysis
11.31 Oracle Corporation.
11.31.1 Company Overview
11.31.2 Role of Oracle Corporation in Global Precision Medicine Market
11.31.3 Financials
11.31.4 Key Insights about Financial Health of the Company
11.31.5 SWOT Analysis
11.32 Pacific Biosciences of California, Inc.
11.32.1 Company Overview
11.32.2 Role of Pacific Biosciences of California, Inc. in Global Precision Medicine Market
11.32.3 Financials
11.32.4 Key Insights About Financial Health of the Company
11.32.5 SWOT Analysis
11.33 Partek, Inc.
11.33.1 Company Overview
11.33.2 Role Partek, Inc. in Global Precision Medicine Market
11.33.3 SWOT Analysis
11.34 Pfizer Inc.
11.34.1 Company Overview
11.34.2 Role of Pfizer, Inc. in Global Precision Medicine Market
11.34.3 Financials
11.34.4 Key Insights about Financial Health of the Company
11.34.5 SWOT Analysis
11.35 QIAGEN N.V.*
11.35.1 Company Overview
11.35.2 Role of QIAGEN N.V. in Global Precision Medicine Market
11.35.3 Financials
11.35.4 Key Insights About Financial Health of the Company
11.35.5 SWOT Analysis
11.36 Quest Diagnostics Incorporated
11.36.1 Company Overview
11.36.2 Role of Quest Diagnostics Incorporated in Global Precision Medicine Market
11.36.3 Financials
11.36.4 SWOT Analysis
11.37 Randox Laboratories Ltd.
11.37.1 Company Overview
11.37.2 Role of Randox Laboratories Ltd. in Global Precision Medicine Market
11.37.3 SWOT Analysis
11.38 Sanofi S.A.
11.38.1 Company Overview
11.38.2 Role of Sanofi SA in Global Precision Medicine Market
11.38.3 Financials
11.38.4 Key Insights about Financial Health of the Company
11.38.5 SWOT Analysis
11.39 Sysmex Corporation
11.39.1 Company Overview
11.39.2 Role of Sysmex Corporation in Global Precision Medicine Market
11.39.3 Financials
11.39.4 Key Insights about Financial Health of the Company
11.39.5 SWOT Analysis
11.40 Teva Pharmaceuticals Industries Ltd.
11.40.1 Company Overview
11.40.2 Role of Teva Pharmaceuticals Industries Ltd. in Global Precision Medicine Market
11.40.3 Financials
11.40.4 Key Insights about Financial Health of the Company
11.40.5 SWOT Analysis
11.41 Thermo Fisher Scientific Inc.
11.41.1 Company Overview
11.41.2 Role of Thermo Fisher Scientific Inc. in Global Precision Medicine Market
11.41.3 Financials
11.41.4 Key Insights About Financial Health of the Company
11.41.5 SWOT Analysis
List of Tables
Table 4.1: Initiatives and Programs
Table 5.1: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)
Table 5.2: Estimated Number of Cancer Incident Cases for 2018 and 2040
Table 5.3: Policy and Guidance Documents from the U.S. FDA
Table 6.1: Pipeline Analysis (by Company)
Table 6.2: Pipeline Analysis (by Product)
Table 6.3: Precision Medicine Drugs Pipeline Analysis
Table 8.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labeling
Table 8.2: Key Approved Therapeutics with FDA-Mandated Companion Diagnostics Tests
Table 8.3: List of FDA Approved Companion Diagnostics
Table 8.4: Commercially Available Primary and Secondary Analysis Tools Providers
Table 9.1: Cancer Precision Medicine Drugs and Indications
Table 9.2: Infectious Diseases Precision Medicine Drugs and Indications
Table 9.3: Neurology Precision Medicine Drugs and Indications
Table 9.4: Cardiovascular Precision Medicine Drugs/Tests/ and Indications
Table 9.5: Endocrinology Precision Medicine Drugs and Indications
Table 9.6: Gastroenterology Precision Medicine Drugs and Indications
Table 9.7: Precision Drugs for Other Applications
Table 10.1: Funding scenario in Universities
List of Figures
Figure 1: Precision Medicine: Treatment Tailored to an Individual’s Genetic Structure
Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care
Figure 3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 4: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Medicine Market
Figure 5: Global Precision Medicine Market (by Ecosystem), 2019 vs. 2030 ($Billion)
Figure 6: Global Precision Medicine Market (by Application Area), 2019 vs. 2030 ($Billion)
Figure 7: Global Precision Medicine Market (by Region) Snapshot
Figure 1.1: Global Precision Medicine Market Segmentation
Figure 1.2: Global Precision Medicine Market Methodology
Figure 3.1: Primary Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.1: Precision Medicine Approach
Figure 4.2: Evolution of Precision Medicine Technology
Figure 4.3: Precision Medicine: Enabling Technologies and Applications
Figure 4.4: Structured Big Data Reporting Benefits
Figure 4.5: Generalized Process for the Microarray
Figure 4.6: Global Precision Medicine Market: COVID-19 Impact
Figure 5.1: Impact Analysis
Figure 5.2: Percent of Patients Whose Tumor Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
Figure 6.1: Patent Analysis
Figure 6.2: Role of FDA in Advancing Precision Medicine
Figure 6.3: FDA Guidelines for CDx Approval
Figure 7.1: Share of Key Developments and Strategies, January 2012–July 2020
Figure 7.2: Synergistic Activities (January 2012- July 2020)
Figure 7.3: Product launches, Enhancements, and Upgradation by Companies (January 2012-July 2020)
Figure 7.4: Product Approvals by Companies (January 2012-July 2020)
Figure 7.5: Merger and Acquisitions Share by Companies (January 2012-July 2020)
Figure 7.6: Business Expansion Share by Companies (January 2012-July 2020)
Figure 7.7: Market Share Analysis for PM Applied Sciences Ecosystem, 2019
Figure 7.8: Market Share Analysis for PM Diagnostics Ecosystem, 2019
Figure 7.9: Market Share Analysis by PM Therapeutics Ecosystem, 2019
Figure 7.10: Market Share Analysis by PM Digital Health and IT Ecosystem, 2019
Figure 7.11: Share of Key Developments and Strategies, January 2014–February 2020
Figure 8.1: Precision Medicine: The Ecosystem
Figure 8.2: Global Precision Medicine Market (by Ecosystem)
Figure 8.3: Global Precision Medicine Market (by Ecosystem), 2019-2030
Figure 8.4: Global Precision Medicine Market (by Applied Sciences)
Figure 8.5: Global Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 8.6: Precision Medicine: Multi-omics Sciences
Figure 8.7: Global Precision Medicine Applied Sciences Market (by Type), 2019-2030
Figure 8.8: Precision Medicine: Genomics
Figure 8.9: Global Precision Medicine Genomics Market, 2019-2030
Figure 8.10: Global Precision Medicine Genomics Market (by Technology), 2019-2030
Figure 8.11: Global Precision Medicine PCR Market, 2019-2030
Figure 8.12: Global Precision Medicine PCR Market (by Product ), 2019-2030
Figure 8.13: Global Precision Medicine PCR Market (by End User), 2019-2030
Figure 8.14: Global Precision Medicine PCR Market (by Region), 2019-2030
Figure 8.15: Evolution of Next-Generation Sequencing
Figure 8.16: Global Precision Medicine NGS Market, 2019-2030
Figure 8.17: Global Precision Medicine NGS Market (by Product), 2019-2030
Figure 8.18: Global Precision Medicine NGS Market (by Technology), 2019-2030
Figure 8.19: Global Precision Medicine NGS Market (by End User), 2019-2030
Figure 8.20: Global Precision Medicine NGS Market (by Region), 2019-2030
Figure 8.21: Global Precision Medicine Genome Editing Market, 2019-2030
Figure 8.22: Global Precision Medicine Genome Editing Market (by Product), 2019-2030
Figure 8.23: Global Precision Medicine Genome Editing Market (by End User), 2019-2030
Figure 8.24: Global Precision Medicine Genome Editing Market (by Region), 2019-2030
Figure 8.25: Global Precision Medicine Other Technologies Market, 2019-2030
Figure 8.26: Global Precision Medicine Other Technologies Market (by Region), 2019-2030
Figure 8.27: Role of Biomarkers in Pharmacogenomics
Figure 8.28: Role of FDA In Pharmacogenomics
Figure 8.29: Global Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 8.30: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2019-2030
Figure 8.31: Global Precision Medicine Pharmacogenomics Market (by End User), 2019-2030
Figure 8.32: Global Precision Medicine Pharmacogenomics Market (by Region), 2019-2030
Figure 8.33: Global Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 8.34: Precision Medicine: Diagnostics
Figure 8.35: Global Precision Medicine Market (by Precision Diagnostics)
Figure 8.36: Global Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 8.37: Global Precision Medicine Diagnostics Market (by Type), 2019-2030
Figure 8.38: General Workflow of a Molecular Diagnostic Assay
Figure 8.39: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
Figure 8.40: Global Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 8.41: Global Precision Medicine Molecular Diagnostics Market (by Type), 2019-2030
Figure 8.42: Benefits and Risks Associated with NIPT
Figure 8.43: Global Precision Medicine NIPT Market, 2019-2030
Figure 8.44: Global Precision Medicine NIPT Market (by Platform), 2019-2030
Figure 8.45: Global Precision Medicine NIPT Market (by Region), 2019-2030
Figure 8.46: Drug and Companion Diagnostics Development Process
Figure 8.47: Benefits and Risks Associated with Companion Diagnostics
Figure 8.48: Global Precision Medicine Companion Diagnostics Market, 2019-2030
Figure 8.49: Global Precision Medicine Companion Diagnostics Market (by Technology), 2019-2030
Figure 8.50: Global Precision Medicine Companion Diagnostics Market (by Indication), 2019-2030
Figure 8.51: Global Precision Medicine Companion Diagnostics Market (by Region), 2019-2030
Figure 8.52: Clinical Applications of Liquid Biopsy
Figure 8.53: Global Precision Medicine Liquid Biopsy Market, 2019-2030
Figure 8.54: Global Precision Medicine Liquid Biopsy Market (by Indication), 2019-2030
Figure 8.55: Global Precision Medicine Liquid Biopsy Market (by Region), 2019-2030
Figure 8.56: Global Precision Medicine Other Molecular Diagnostics Market, 2020-2030
Figure 8.57: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2019-2030
Figure 8.58: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2019-2030
Figure 8.59: Global Precision Medicine Medical Imaging Market, 2019-2030
Figure 8.60: Global Precision Medicine Medical Imaging Market (by Type), 2019-2030
Figure 8.61: Global Precision Medicine Imaging Analytics Market, 2019-2030
Figure 8.62: Global Precision Medicine CADx Market, 2019-2030
Figure 8.63: Global Precision Medicine Medical Imaging Market (by Region), 2019-2030
Figure 8.64: Global Precision Medicine Digital Health and Information Technology Market, 2019-2030
Figure 8.65: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2019-2030
Figure 8.66: Global Precision Medicine CDSS Market, 2019-2030
Figure 8.67: Big Data Attributes
Figure 8.68: Global Precision Medicine Big Data Analytics Market, 2019-2030
Figure 8.69: Big Data Analytics: Key Benefits
Figure 8.70: Global Precision Medicine IT Infrastructure Market, 2019-2030
Figure 8.71: Global Precision Medicine IT Infrastructure Market (by Type), 2019-2030
Figure 8.72: Global Precision Medicine Genomics Informatics Market, 2019-2030
Figure 8.73: Global Precision Medicine Genomics Informatics Market (by Product Type), 2019-2030
Figure 8.74: Global Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 8.75: Global Precision Medicine Mobile Health Market, 2019-2030
Figure 8.76: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2019-2030
Figure 8.77: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2019-2030
Figure 8.78: Global Precision Medicine Therapeutics Market, 2019-2030
Figure 8.79: Global Precision Medicine Therapeutics Market (by Type), 2019-2030
Figure 8.80: Global Precision Medicine Clinical Trials Market, 2019-2030
Figure 8.81: Global Precision Medicine Clinical Trials Market (by Region), 2019-2030
Figure 8.82: Types of Cell Therapy
Figure 8.83: Global Precision Medicine Cell Therapy Market, 2019-2030
Figure 8.84: Global Precision Medicine Cell Therapy Market (by Region), 2019-2030
Figure 8.85: Global Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 8.86: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
Figure 8.87: Types of Gene Therapy
Figure 8.88: Types of Gene Therapy
Figure 8.89: Global Precision Medicine Gene Therapy Market, 2019-2030
Figure 8.90: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030
Figure 9.1: Global Precision Medicine Applications Market, 2019-2030
Figure 9.2: Types of Cancer
Figure 9.3: Global Precision Medicine Oncology Market, 2019-2030
Figure 9.4: Global Precision Medicine Infectious Diseases Market, 2019-2030
Figure 9.5: Number of Deaths by Top 18 Infectious Diseases, 2018
Figure 9.6: Global Precision Medicine Neurology Market, 2019-2030
Figure 9.7: Global Precision Medicine Cardiovascular Market, 2019-2030
Figure 9.8: Global Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
Figure 9.9: Global Precision Medicine Gastroenterology Market, 2019-2030
Figure 9.10: Global Precision Medicine Other Applications Market, 2019-2030
Figure 10.1: Global Precision Medicine Market (by Region), 2019 and 2030
Figure 10.2: Global Precision Medicine Market (by Region), 2019-2030
Figure 10.3: North America Precision Medicine Market, 2019-2030
Figure 10.4: North America: Market Dynamics
Figure 10.5: North America Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.6: North America Precision Medicine Market (by Country), 2019-2030
Figure 10.7: U.S. Precision Medicine Market, 2019-2030
Figure 10.9: Europe Precision Medicine Market, 2019-2030
Figure 10.10: Europe: Market Dynamics
Figure 10.11: Europe Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.12: Europe Precision Medicine Market (by Country), 2019-2030
Figure 10.13: Germany Precision Medicine Market, 2019-2030
Figure 10.14: France Precision Medicine Market, 2019-2030
Figure 10.15: Italy Precision Medicine Market, 2019-2030
Figure 10.16: The U.K. Precision Medicine Market, 2019-2030
Figure 10.17: Spain Precision Medicine Market, 2019-2030
Figure 10.18: Rest-of-Europe Precision Medicine Market, 2019-2030
Figure 10.19: Asia-Pacific Precision Medicine Market, 2019-2030
Figure 10.20: APAC: Market Dynamics
Figure 10.21: Asia-Pacific Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.22: Asia-Pacific Precision Medicine Market (by Country), 2019-2030
Figure 10.23: China Precision Medicine Market, 2019-2030
Figure 10.24: Japan Precision Medicine Market, 2019-2030
Figure 10.25: Australia Precision Medicine Market, 2019-2030
Figure 10.26: India Precision Medicine Market, 2019-2030
Figure 10.27: Rest-of-Asia-Pacific Precision Medicine Market, 2019-2030
Figure 10.28: Latin America Precision Medicine Market, 2019-2030
Figure 10.29: APAC: Market Dynamics
Figure 10.30: Latin America Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.31: Latin America Precision Medicine Market (by Country), 2019-2030
Figure 10.32: Brazil Precision Medicine Market, 2019-2030
Figure 10.33: Mexico Precision Medicine Market, 2019-2030
Figure 10.34: Rest-of-Latin America Precision Medicine Market, 2019-2030
Figure 10.35: Rest-of-the-World Precision Medicine Market (by Ecosystem), 2019-2030
Figure 10.36: Rest-of-the-World Precision Medicine Market, 2019-2030
Figure 11.1: Total Number of Companies Profiled
Figure 11.2: Abbott Laboratories: Product Portfolio
Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 11.7: Abbott Laboratories: SWOT Analysis
Figure 11.8: Almac Group Ltd.: SWOT Analysis
Figure 11.9: Abbott Laboratories: Product Portfolio
Figure 11.10: Amgen Inc.: Overall Financials, 2017-2019
Figure 11.11: Amgen Inc.: Revenue (by Region), 2018-2019
Figure 11.12: Amgen Inc. R&D Expenditure, 2017-2019
Figure 11.13: Amgen Inc.: SWOT Analysis
Figure 11.14: ANGLE plc: Overall Financials, 2017-2019
Figure 11.15: ANGLE plc: Revenue (by Region), 2018-2019
Figure 11.16: ANGLE plc R&D Expenditure, 2017-2019
Figure 11.17: ANGLE plc: SWOT Analysis
Figure 11.18: Astellas Pharma Inc.: Product Portfolio
Figure 11.19: Astellas Pharma Inc.: Overall Financials, 2017-2019
Figure 11.20: Astellas Pharma Inc. R&D Expenditure, 2017-2019
Figure 11.21: Astellas Pharma Inc.: SWOT Analysis
Figure 11.22: Astra Zeneca: Product Portfolio
Figure 11.23: Astra Zeneca: Overall Financials, 2017-2019
Figure 11.24: Astra Zeneca: Revenue (by Business Segment), 2017-2019
Figure 11.25: Astra Zeneca: Revenue (by Region), 2017-2019
Figure 11.26: Astra Zeneca: SWOT Analysis
Figure 11.27: ASURAGEN INC.: SWOT Analysis
Figure 11.28: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 11.29: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 11.30: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 11.31: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
Figure 11.32: Bio-Rad Laboratories, Inc: SWOT Analysis
Figure 11.33: bioMérieux S.A.: Product Portfolio
Figure 11.34: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 11.35: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 11.36: bioMérieux S.A.: Revenue (by Region), 2018-2019
Figure 11.37: bioMérieux S.A.: SWOT Analysis
Figure 11.38: Bristol-Myers Squibb Company: Product Portfolio
Figure 11.39: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 11.40: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
Figure 11.41: Bristol-Myers Squibb Company.: SWOT Analysis
Figure 11.42: Cardiff Oncology.: Product Portfolio
Figure 11.43: Cardiff Oncology: Overall Financials, 2018-2019
Figure 11.44: Cardiff Oncology: R&D Expenditure, 2018-2019
Figure 11.45: Cardiff Oncology: SWOT Analysis
Figure 11.46: CETICS Healthcare Technologies GmbH: SWOT Analysis
Figure 11.47: Danaher Corporation: Overall Financials, 2017-2019
Figure 11.48: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 11.49: Danaher Corporation: SWOT Analysis
Figure 11.50: Eli Lilly and Company Limited: Product Portfolio
Figure 11.51: Eli Lilly and Company Limited: Overall Financials, 2017-2019
Figure 11.52: Eli Lilly and Company Limited: Revenue (by Region), 2018-2019
Figure 11.53: Eli Lilly and Company Limited: SWOT Analysis
Figure 11.54: Epic Sciences, Inc.: Product Portfolio
Figure 11.55: Epic Sciences, Inc.: SWOT Analysis
Figure 11.56: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 11.57: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 11.58: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 11.59: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 11.60: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 11.61: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 11.62: GE Healthcare: Product Portfolio
Figure 11.63: General Electric Company: Overall Financials, 2017-2019
Figure 11.64: General Electric Company: Revenue Split for Healthcare, 2017-2019
Figure 11.65: General Electric: Healthcare Revenue (by Region), 2017-2019
Figure 11.66: General Electric Company: R&D Expenditure, 2017-2019
Figure 11.67: General Electric Company: SWOT Analysis
Figure 11.68: Gilead Sciences, Inc.: Product Portfolio
Figure 11.69: Gilead Science, Inc.: SWOT Analysis
Figure 11.70: GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 11.71: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 11.72: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 11.73: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 11.74: GlaxoSmithKline plc: SWOT Analysis
Figure 11.75: Illumina, Inc.: Product Portfolio
Figure 11.76: Illumina, Inc.: Overall Financials, 2017-2019
Figure 11.77: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 11.78: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 11.79: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 11.80: Illumina, Inc.: SWOT Analysis
Figure 11.81: Intomics A/S: SWOT Analysis
Figure 11.82: Illumina, Inc.: Product Portfolio
Figure 11.83: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
Figure 11.84: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
Figure 11.85: Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 11.86: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 11.87: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 11.88: Konica Minolta, Inc.: SWOT Analysis
Figure 11.89: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 11.90: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 11.91: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 11.92: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 11.93: MDx Health, Inc.: Overall Financials, 2017--2019
Figure 11.94: MDx Health, Inc.: SWOT Analysis
Figure 11.95: Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure 11.96: Merck KGaA: Product Portfolio
Figure 11.97: Merck KGaA: Overall Financials, 2017-2019
Figure 11.98: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 11.99: Merck KGaA: Revenue (by Region), 2017-2019
Figure 11.100: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
Figure 11.101: Merck KGaA: R&D Expenditure, 2017-2019
Figure 11.102: Merck KGaA: SWOT Analysis
Figure 11.103: Myriad Genetics, Inc.: Product Portfolio
Figure 11.104: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 11.105: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 11.106: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 11.107: Myriad Genetics, Inc.: SWOT Analysis
Figure 11.108: Novartis AG: Overall Product Portfolio
Figure 11.109: Novartis AG: Overall Financials, 2017-2019
Figure 11.110: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 11.111: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 11.112: Novartis AG: R& D Expense, 2017-2019
Figure 11.113: Novartis AG: SWOT Analysis
Figure 11.114: Oracle Corporation: Overall Financials, 2017-2019
Figure 11.115: Oracle Corporation: Revenue (by Region), 2017-2019
Figure 11.116: Oracle Corporation R&D Expenditure, 2017-2019
Figure 11.118: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 11.119: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 11.120: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 11.121: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 11.122: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 11.123: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 11.124: Partek, Inc.: SWOT Analysis
Figure 11.125: Pfizer Inc.: Overall Product Portfolio
Figure 11.126: Pfizer Inc.: Overall Financials, 2017-2019
Figure 11.127: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 11.128: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 11.129: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 11.130: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 11.131: Pfizer Inc.: SWOT Analysis
Figure 11.132: QIAGEN N.V.: Portfolio
Figure 11.133: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 11.134: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 11.135: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 11.136: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 11.137: QIAGEN N.V.: SWOT Analysis
Figure 11.138: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 11.139: Quest Diagnostics Incorporated: SWOT Analysis
Figure 11.140: Randox Laboratories Ltd.: SWOT Analysis
Figure 11.141: Sanofi SA: Product Portfolio
Figure 11.142: Sanofi SA: Overall Financials, 2017-2019
Figure 11.143: Sanofi SA: Revenue (by Segment), 2017-2019
Figure 11.144: Sanofi SA: Revenue (by Region), 2017-2019
Figure 11.145: Sanofi SA: R&D Expenditure, 2017-2019
Figure 11.146: Sanofi SA: SWOT Analysis
Figure 11.147: Sysmex Corporation: Overall Financials, 2017-2019
Figure 11.148: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
Figure 11.149: Sysmex Corporation R&D Expenditure, 2017-2019
Figure 11.150: Sysmex Corporation: SWOT Analysis
Figure 11.151: Teva Pharmaceuticals Industries Ltd.: Product Portfolio
Figure 11.152: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
Figure 11.153: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
Figure 11.154: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
Figure 11.155: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
Figure 11.156: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 11.157: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 11.158: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 11.159: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 11.160: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 11.161: Thermo Fisher Scientific Inc.: SWOT Analysis
FAQ's
Q. What is the estimated growth rate of the global precision medicine market in the coming years?
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
Q. What are the possible factors driving the growth of the precision medicine market?
Factors driving the growth of the market including advancement of sequencing technologies, rising prevalence of chronic diseases, growing demand for preventive care, and shifting the significance in medicine from reaction to prevention.
Q. What are potential opportunities that aid the growth of precision medicine market?
Potential opportunities that can boost the growth of the market include targeted gene therapy, expansion into the emerging markets, and collaborations and partnerships across value chain to accelerate the market entry.
Q. What are the enabling technologies covered in precision medicine market?
The enabling technologies associated with precision medicine include innovators, early adopters, early majority, and late majority.
Q. Which are the top market players operating in the precision medicine market?
Some of the key companies operating in the market Abbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMérieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, and Gilead Sciences, Inc.
You may also like
Published Year: 2019
Global Next-Generation Sequencing Market: Focus on Products and Services, Applications, Technology,
In 2018, the global next-generation sequencing market was valued at $4.93 billion and is...
Global Precision Medicine Market
Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030